Schizophrenia Bulletin

• 

  Publication Venue For

  • Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.  42:425-433. 2016
  • 3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA.  35:151-151. 2009
  • Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia..  35:336-346. 2009
  • EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA.  35:356-357. 2009
  • NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD.  35:368-368. 2009
  • Voxel-based morphometric multisite collaborative study on schizophrenia..  35:82-95. 2009
  • fMRI activity correlated with auditory hallucinations during performance of a working memory task: data from the FBIRN consortium study..  35:47-57. 2009
  • Implementation considerations for multisite clinical trials with cognitive neuroscience tasks..  34:656-663. 2008
  • How should DSM-V criteria for schizophrenia include cognitive impairment?.  33:912-920. 2007
  • A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia..  31:5-19. 2005
  • Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment..  30:3-20. 2004
  • Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia..  30:587-598. 2004
  • Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates..  30:45-57. 2004
  • Revised PORT recommendations..  30:609-611. 2004
  • The Texas medication algorithm project: clinical results for schizophrenia..  30:627-647. 2004
  • The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients..  30:577-586. 2004
  • Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial..  29:33-43. 2003
  • Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale..  29:45-55. 2003
  • The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development..  29:15-31. 2003
  • Concealed medicines for people with schizophrenia: a U.S. perspective..  28:537-542. 2002
  • Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia..  27:697-708. 2001
  • The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis..  25:201-222. 1999
  • Common sense, insight, and neuropsychological test performance in schizophrenia patients..  22:635-641. 1996
  • DEFICIENT VISUAL ODDBALL STIMULUS PROCESSING PREDICTS PSYCHOSIS ONSET: RESULTS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY 2020
  • 26.2 FORMATIVE RESEARCH TO INFORM A CULTURALLY TAILORED FAMILY PSYCHOEDUCATION INTERVENTION FOR ADULTS WITH PSYCHOTIC DISORDERS IN TANZANIA 2019
  • 16.1 EPIGENETIC SIGNATURES OF CHILDHOOD AND ADOLESCENT VICTIMISATION USING A GENETICALLY SENSITIVE LONGITUDINAL COHORT STUDY. 2018
  • O12.3. PROTECTIVE FACTORS FOR PSYCHOTIC EXPERIENCES AMONGST ADOLESCENTS EXPOSED TO MULTIPLE FORMS OF VICTIMIZATION 2018
  • O8.3. CLINICAL AND FUNCTIONAL OUTCOMES IN YOUNG ADULTHOOD OF CHILDREN WITH PSYCHOTIC SYMPTOMS: A LONGITUDINAL TWIN COHORT STUDY 2018
  • RANDOMIZED CONTROLLED TRIAL OF A NEUROSTEROID INTERVENTION IN SCHIZOPHRENIA 2017
  • EFFECTS OF COGNITIVE REMEDIATION ON NEGATIVE SYMPTOMS DIMENSIONS: EXPLORING THE ROLE OF WORKING MEMORY 2015
  • FINDING THE SITES OF GLUTAMATE CIRCUITRY ABNORMALITY IN SCHIZOPHRENIA WITH PROTON MRS 2015
  • GABA AND GLUTAMATE DYSFUNCTION IN SCHIZOPHRENIA: DISTINGUISHING MEDICATION EFFECTS FROM NEUROBIOLOGY 2015
  • MODELING THE EXPRESSION AND COURSE OF DEVELOPMENTAL ABNORMALITIES PRECEDING ADULT SCHIZOPHRENIA: CHARACTERIZATION OF A NEW DEVELOPMENTAL ULTRA-HIGH-RISK GROUP IN 2 BIRTH COHORTS 2011
  • SLEEP PATTERNS OF INDIVIDUALS WITH SCHIZOPHRENIA 2011
  • FRONTAL CORTEX GABA, OSCILLATIONS, AND WORKING MEMORY IN SCHIZOPHRENIA 2011
  • DEVELOPMENT OF AN INTERVIEW-BASED "CO-PRIMARY'' MEASURE OF COGNITION 2009
  • DIFFERENTIATING VOLITION FROM HEDONIA USING A MONITARY REWARD TASK DURING FMRI 2009
  • EVALUATION OF THE EFFECTS OF AL-108 ON NEUROCOGNITION IN SCHIZOPHRENIA: INITIAL TURNS STUDY RESULTS 2009
  • Clozapine increases the neurosteroid pregnenolone in rat hippocampus, cerebral cortex, and serum: Relevance to superior efficacy? 2007
  • Pregnenolone reductions in parietal cortex are associated with suicide in patients with schizophrenia 2007
  • A brief cognitive assessment tool for schizophrenia (B-CATS): Scale construction 2007
  • Efficiency of the BACS and CATIE neuropsychological batteries in assessing cognition and antipsychotic treatment related change in cognition during the CAFE clinical trial 2007
  • Disrupted task related activation to action selection and conflict resolution in patients with schizophrenia 2005
  • Neuroactive steroid alterations in schizophrenia and bipolar disorder: Negative ion chemical ionization gas chromatography/mass spectrometry investigations in posterior cingulate and parietal cortex 2005
  • Neuropsychological deficits at age 13 and later schizophreniform disorder: A longitudinal birth cohort study 2005
  • Olanzapine and fluoxetine effects on hippocampal pregnenolone and peripheral deoxycorticosterone: Relevance to therapeutic efficacy 2005